BioNTech (NASDAQ:BNTX) Sees Unusually-High Trading Volume – Still a Buy?

BioNTech SE (NASDAQ:BNTX) saw an uptick in trading volume on Tuesday . 254,365 shares traded hands during trading, a decline of 46% from the previous session’s volume of 469,307 shares.The stock last traded at $127.06 and had previously closed at $120.21.

Analyst Ratings Changes

Several research analysts have recently weighed in on BNTX shares. Canaccord Genuity Group lifted their target price on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Berenberg Bank assumed coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. decreased their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Stock Down 3.7 %

The stock has a market cap of $29.28 billion, a P/E ratio of -58.17 and a beta of 0.18. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $113.89 and a 200-day simple moving average of $102.93.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business posted $0.73 earnings per share. The firm’s revenue was up 38.9% compared to the same quarter last year. Analysts expect that BioNTech SE will post -3.72 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently modified their holdings of the business. TD Asset Management Inc lifted its stake in shares of BioNTech by 6.1% in the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after buying an additional 435 shares during the period. Caprock Group LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth approximately $206,000. Choreo LLC bought a new stake in shares of BioNTech during the second quarter valued at approximately $690,000. Daiwa Securities Group Inc. lifted its position in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its stake in BioNTech by 3.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 427,597 shares of the company’s stock worth $34,533,000 after buying an additional 15,700 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.